Tax-driven stock sale by Vera Therapeutics (NASDAQ: VERA) CFO

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics, Inc. chief financial officer Sean Grant reported an open‑market sale of 4,949 shares of Class A common stock at a weighted‑average price of $41.9839 per share. According to the disclosure, the transaction was a mandated sell‑to‑cover trade to satisfy tax withholding obligations from vesting restricted stock units rather than a discretionary sale.

After this transaction, Grant directly held 114,181 Vera Therapeutics shares and indirectly held 5,000 additional shares through a trust. The sale occurred as part of trading orders executed over two business days beginning on February 23, 2026 and ending on February 24, 2026.

Insider Trade Summary

Net Seller: 4,949 shares ($207,778)

Net Sell 2 txns

Insider Grant Sean

Role CHIEF FINANCIAL OFFICER

Sold 4,949 shs ($208K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	4,949	$41.9839	$208K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 114,181 shares (Direct); Class A Common Stock — 5,000 shares (Indirect, By Trust)

Footnotes (1)

The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

02/25/2026 - 07:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grant Sean

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/23/2026⁽¹⁾	02/24/2026	S⁽²⁾		4,949	D	$41.9839⁽³⁾	114,181	D
Class A Common Stock								5,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.

2. Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

3. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

	/s/ Joseph R. Young, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vera Therapeutics (VERA) disclose for its CFO?

Vera Therapeutics disclosed that CFO Sean Grant sold 4,949 shares of Class A common stock in an open‑market transaction. The filing explains this was a sell‑to‑cover sale required to pay tax withholding on vesting restricted stock units, not a discretionary stock sale.

At what price were the Vera Therapeutics (VERA) shares sold by the CFO?

The 4,949 Vera Therapeutics shares sold by CFO Sean Grant had a weighted‑average price of $41.9839 per share. The filing notes they were executed in multiple trades within a price range from $41.005 to $42.84, and detailed breakdowns are available upon request.

Why did the Vera Therapeutics (VERA) CFO sell shares in this Form 4 filing?

The filing states the CFO’s share sale was solely to cover tax withholding obligations triggered by vesting restricted stock units. Under the company’s equity incentive plans, these obligations were satisfied through a mandated sell‑to‑cover transaction, meaning the trade was not an elective disposal of shares.

How many Vera Therapeutics (VERA) shares does the CFO hold after the reported sale?

After the reported sell‑to‑cover transaction, CFO Sean Grant directly held 114,181 shares of Vera Therapeutics Class A common stock. He also indirectly held an additional 5,000 shares through a trust, as indicated by the indirect ownership line referencing “By Trust” in the filing.

Over what period were the Vera Therapeutics (VERA) CFO’s shares sold?

The filing explains that trading orders related to the sell‑to‑cover tax transaction were executed over two business days. This period began on February 23, 2026 and ended on February 24, 2026, covering all participant RSU tax‑related sales, including those for the CFO.

Were the Vera Therapeutics (VERA) CFO’s stock sales discretionary open‑market trades?

No. Footnotes clarify that the Vera Therapeutics CFO’s stock sales were mandated under the company’s equity incentive plans to fund tax withholding via sell‑to‑cover transactions. The filing explicitly states these transactions do not represent discretionary trades initiated by the reporting person.